Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Fund Details
Upturn AI Summary
Tema Oncology ETF(CANC)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for CANC
10/13/2026: CANC (2-star) is currently NOT-A-BUY. Pass it for now.
The Tema Oncology ETF (CANC) provides actively managed exposure to the global oncology sector, targeting companies at the forefront of cancer treatment and research. Its primary strength lies in its specialized research-led strategy, which aims to identify winners in a complex and high-growth industry. The fund is designed for investors seeking targeted thematic growth rather than broad healthcare diversification. Key risks include significant volatility stemming from clinical trial success or failure, regulatory pricing pressures, and the fund's relatively low liquidity. It is best suited for growth-oriented investors with high risk tolerance who are looking to complement a diversified portfolio with concentrated biotech exposure.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The focus on cutting-edge oncology innovation aligns well with growth-oriented investment mandates. |
| Momentum investor | Mixed fit | Momentum suitability is conditional on a positive Upturn signal in the biotech sector and individual holding performance. |
| Value investor | Weak fit | The fund holds speculative, research-heavy companies that often lack traditional value metrics. |
| Dividend/Income investor | Weak fit | Most companies in this sector reinvest capital into research rather than paying dividends. |
| Low-risk investor | Weak fit | The high volatility of the biotech sector is incompatible with low-risk investment profiles. |
Investor Profile
Ideal Investor Profile
An investor with a high risk tolerance and a long-term time horizon looking to gain targeted exposure to cancer research innovation.
Suitability
Best suited for long-term investors who can withstand short-term volatility and believe in the long-term growth of oncology therapeutics.
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Volatility | High | Biotech stocks are prone to significant price swings based on clinical trial outcomes. |
| Market risk | Medium / high | Broader healthcare sector downturns will directly impact the fund's net asset value. |
| Concentration | High | The fund is restricted to oncology, which limits diversification compared to total market funds. |
| Tracking/expense | Medium | The active management fee is higher than passive alternatives, requiring alpha to justify the cost. |
| Liquidity | Medium / high | Lower trading volume may lead to higher execution costs for retail investors. |
| Business/sector quality | Medium / high | The sector depends on regulatory approvals, creating binary risks for many holdings. |
Risk Analysis
Volatility
CANC exhibits high volatility typical of thematic biotech investments.
Market Risk
Risks include binary outcomes from clinical trials and sector-wide sensitivity to interest rates and regulatory policy.
What the ETF Owns
| Exposure Type | Exposure | Weight (%) | Retail Investor Read |
|---|---|---|---|
| Sector | Biotechnology and Pharmaceuticals (Oncology Focus) | 95 | This exposure provides targeted investment in firms developing cancer-related therapies and diagnostic tools. |
| Cash/collateral | Cash and Cash Equivalents | 5 | The fund maintains a small cash buffer for liquidity and rebalancing purposes. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Smooth
The stock has moved along a generally orderly path with only modest fluctuations.
Analysis of Past Performance
Type ETF | Historic Profit 57.1% | Avg. Invested days 72 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  5.0 | ETF Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/13/2026 |
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.